Biogen Idec, Inc. (Massachusetts) (BIIB) First Quarter 2014 Revenues Reach $2.1 Billion Driven By Continued Strength Of MS Franchise
4/23/2014 7:23:34 AM
Biogen Idec Inc. (NASDAQ: BIIB) today reported first quarter 2014 results, including revenue of $2.1 billion, a 51% increase compared to the first quarter of 2013. The revenue growth year-over-year was driven by strong TECFIDERA performance and from recording 100% of TYSABRI® revenues following our acquisition of complete rights for the asset in the second quarter of 2013. First quarter 2014 non-GAAP diluted earnings per share (EPS) were $2.47, an increase of 25% over the first quarter of 2013. Non-GAAP net income attributable to Biogen Idec for the year was $587 million, an increase of 25% over the first quarter of 2013.
Help employers find you! Check out all the jobs and post your resume.
comments powered by